The following is a round-up of earnings for London-listed companies, issued on Monday and not separately reported by Alliance News:
----------
Silver Bullet Data Services Group PLC - London-based marketing services provider - Pretax loss widens to £2.1 million in the six months that ended June 30 from £1.6 million a year before, despite revenue rising by 9.1% to £4.8 million from £4.4 million. Higher personnel costs, depreciation and amortisation, and an exceptional item for ‘potential costs in relation to business acquisitions’ cause Silver Bullet’s operating loss to widen to £1.5 million from £1.3 million a year before. What’s more, finance expense doubles to £671,428 from £288,854. Loss before interest, tax, depreciation and amortisation is £1.1 million, widened slightly from £900,000. Looking ahead, Chief Executive says the board is confident in Silver Bullet’s full-year performance, noting that total bookings secured by the end of August have already surpassed the 2024 total.
----------
Blackbird PLC - London-based video editing software for media and entertainment industry - Pretax loss widens marginally to £1.56 million in the six months that ended June 30 from £1.54 million a year before as revenue slips to £576,895 from £691,643. However, Executive Chair Ian McDonough highlights ‘important milestones’ have been hit since the start of 2025. This include generating positive Ebitda from its Blackbird video editing platform in the first half for the first time in the company’s history. Overall for the company, Ebitda was a loss of £1.1 million in the first half, narrowed from £1.4 million a year before. McDonough also notes a string of contract renewals during the half year and since it has ended. Revenue for 2025 secured as of August 31 is £1.2 million, down from £1.5 million a year before, due to some contract losses. Contracted but unrecognised revenue as of the same date is £1.6 million, up from £1.3 million a year before, with £466,000 of this relating to 2025 and the rest to 2026 and 2027.
----------
Christie Group PLC - London-based provider of professional services, including stock and inventory systems, for customers in the hospitality, leisure, healthcare, medical, childcare, education and retail sectors - Lifts its interim dividend by 50% to 0.75p per share from 0.50p, as it swings to a pretax profit of £905,000 in the six months ended June 30 from a loss of £923,000 a year before. This is thanks to a 24% rise in revenue to £34.8 million from £28.1 million. Christie says it has started the second half of the year with transactional brokerage sales pipelines 15% higher than at the start of the year and financial brokerage instruction levels 10% higher. ‘While our pipelines and ongoing activity levels are encouraging, sensitivity remains as to deal times,’ says Chief Executive Dan Prickett. ‘Adopting a sensible level of prudence, we anticipate a more balanced full-year performance than we delivered in the previous year and remain confident of delivering a full-year performance in line with expectations.’
----------
Physiomics PLC - Oxfordshire, England-based mathematical modelling for the development of new therapeutics and personalised medicines - Pretax loss narrows to £415,254 in the financial year that ended June 30 from £609,352 the year before, as revenue and grant income increase by 46% to £834,156 in total from £570,561. Physiomics says financial 2025 results are in line with market expectations. Looking ahead, it starts financial 2026 with £594,000 in contracted revenue that will be recognised within the year, up from £500,000 at the same point in financial 2025. It also expects £60,000 in grant income in financial 2026. ‘Whilst market conditions are set to remain challenging at least in the short-term, the demand for model-informed drug development and biometrics services is still set to increase,’ Physiomics says.
----------
Poolbeg Pharma PLC - London-based clinical stage biopharmaceutical firm focused on cancer immunotherapy - Pretax loss narrows to £2.18 million in the six months that ended June 30 from £2.26 million a year before. Poolbeg has no revenue, so the narrowed loss is due to a reduction in administrative and research and development expenses. Poolbeg notes that it has a strong cash balance at £10.0 million as of June 30, following its £4.9 million equity raise. It also is positive about its lead drug candidate POLB 001, which has been granted Orphan Drug Designation by the US Food & Drug Administration as an oral preventative therapy for T-cell engager bispecific antibody-induced cytokine release syndrome. ‘Our programmes are in areas of high interest within the pharmaceutical industry,’ says CEO Jeremy Skillington. ‘We are optimistic about the potential of POLB 001 to transform the delivery of cancer immunotherapies by moving administration away from specialist centralised cancer centres and into the community setting, closer to patients’ homes and, as a result, making these life-saving treatments available to more patients.’
----------
Copyright 2025 Alliance News Ltd. All Rights Reserved.
